Clinical Trial: Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naive nAMD Patients

U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07728981) titled 'Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naive nAMD Patients' on July 01.

Brief Summary: Primary objective:

* To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naive nAMD patients.

Secondary objectives:

* To assess the efficacy, safety, and biomarker changes of 8 mg Aflibercept using a modified fixed-interval dosing regimen over 12 months in treatment-naive nAMD patients.

Study Start Date: July 25

Study Type: INTERVENTIONAL

Condition: Neovascular Age-Related...